# Screening of poly-beta amino ester coated emulsion of ketorolac for cartilage delivery

**Authors:** Tahani Saeedi, Polina Prokopovich

PMC · DOI: 10.1039/d4tb00313f · 2024-05-28

## TL;DR

This study explores using PBAE-coated emulsions to deliver ketorolac for osteoarthritis treatment, showing improved drug retention and cartilage protection.

## Contribution

A systematic screening of PBAE polymers for emulsion-based drug delivery to cartilage is presented.

## Key findings

- PBAE-coated emulsions enhanced drug localization in ex vivo cartilage models.
- Optimal PBAE candidates protected chondrocyte viability and increased GAG and collagen contents in damaged cartilage.

## Abstract

Osteoarthritis (OA) is a prevalent chronic health condition necessitating effective treatment strategies. Globally, there were 86 million people with incident knee osteoarthritis in 2020. Pain management remains the primary approach to OA as the nature of cartilage poses challenges for drug delivery. An emulsion-based delivery system, using a class of positively charged and hydrolysable polymers (poly-beta-amino-esters) to coat oil droplets containing drugs, has been shown to enhance and prolong drug localization in ex vivo cartilage models. As the properties of the polymers used in this technology strongly depend on the monomers used in the synthesis, this study presents the screening of a wide range of PBAEs as droplet coating agents and using ketorolac as a model of nonsteroidal anti-inflammatory drugs. The emulsions prepared with this PBAE library were characterized, and drug localisation and retention were evaluated in both native and glycosaminoglycan (GAG) depleted cartilage ex vivo models. Optimal candidates were identified and tested in an ex vivo model showing the ability to protect chondrocyte cell viability and increase both GAG and collagen contents in cartilage exposed to cytokine (IL-1α) simulating acute cartilage damage. This work demonstrates the potential of PBAE coated emulsion as a delivery system for effective drug delivery in OA treatment.

Osteoarthritis (OA) is a prevalent chronic health condition necessitating effective treatment strategies.

## Linked entities

- **Chemicals:** ketorolac (PubChem CID 3826)
- **Diseases:** osteoarthritis (MONDO:0005178)

## Full-text entities

- **Genes:** IL1A (interleukin 1 alpha) [NCBI Gene 3552] {aka IL-1 alpha, IL-1A, IL1, IL1-ALPHA, IL1F1}
- **Diseases:** OA (MESH:D010003), knee osteoarthritis (MESH:D020370), cartilage damage (MESH:D002357), Pain (MESH:D010146)
- **Chemicals:** PBAE (-), ketorolac (MESH:D020910), poly-beta amino ester (MESH:C507253), oil (MESH:D009821), polymers (MESH:D011108), GAG (MESH:D006025)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

26 figures with captions in the complete paper: https://tomesphere.com/paper/PMC11186506/full.md

---
Source: https://tomesphere.com/paper/PMC11186506